Minerva Neurosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 3, 2026, regarding Minerva Neurosciences, Inc. (Nasdaq: NERV). The filing details the results of the Company's 2026 Annual Meeting of Stockholders and subsequent amendments to its governing documents.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes.
Material Changes and Corporate Actions
Stockholders approved two amendments to the Amended and Restated Certificate of Incorporation:
- Exculpation Amendment: Limits the liability of certain officers for monetary damages to the fullest extent permitted by Delaware law.
- Exclusive Forum Amendment: Eliminates the previous exclusive forum provision.
The Board of Directors also approved an amendment and restatement of the Company's Bylaws, effective immediately. Key updates include:
- Clarified authority for the Board to postpone, reschedule, or cancel meetings.
- Updated advance notice provisions for stockholder nominations, including alignment with universal proxy rules (Rule 14a-19).
- Designated federal district courts as the exclusive forum for Securities Act of 1933 claims.
- Added appellate courts from the Court of Chancery as a designated forum for derivative and state law claims.
Voting Results and Management Commentary
As of the record date (April 9, 2026), 43,934,706 shares of common stock were entitled to vote. The final results for the six proposals were:
- Proposal 1 (Election of Directors): Dr. David Kupfer and Jan van Heek were elected. Dr. Kupfer received 23,211,099 votes "For" (with 7,182,190 "Withheld"). Jan van Heek received 30,369,333 votes "For" (with 23,956 "Withheld").
- Proposal 2 (Exculpation Amendment): Approved with 27,222,961 votes "For" and 3,169,756 "Against".
- Proposal 3 (Eliminate Exclusive Forum): Approved with 30,360,809 votes "For" and 20,954 "Against".
- Proposal 4 (Say-on-Pay): Approved with 27,183,828 votes "For" and 3,196,678 "Against".
- Proposal 5 (Say-on-Pay Frequency): Stockholders voted for an annual frequency (1 Year), receiving 30,365,516 votes. The Board determined future advisory votes will be held every year.
- Proposal 6 (Ratification of Auditors): Deloitte & Touche LLP was ratified with 35,289,299 votes "For" and 7,131 "Against".
Investor Verification Checklist
- Review the full text of the Restated Charter (Exhibit 3.1) and Amended and Restated Bylaws (Exhibit 3.2) to understand the specific legal language of the governance changes.
- Verify the impact of the Exculpation Amendment on officer liability protections under Delaware law.
- Confirm the implications of the new exclusive forum provisions for potential securities litigation.
- Monitor the Company's future proxy statements to ensure compliance with the newly adopted universal proxy rules and advance notice procedures.